J&J to buy ARCH-backed eye biotech Ollin for $2.2bn upfront
TLDR
- Johnson & Johnson agreed to buy Ollin Biosciences for $2.2bn upfront, plus milestones of up to about $1.125bn.1
- Blackstone Life Sciences will pay J&J $750M over multiple years to fund Phase 3, contingent on closing.12
- The Financial Times reported the talks on 15 November, putting the total at up to $3.4bn.3
Johnson & Johnson said on 16 November 2026 that it has entered a definitive agreement to acquire Ollin Biosciences, a clinical-stage company developing therapies for serious eye diseases, "for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments".1 The release puts the milestones at up to approximately $1.125 billion and expects closing before the end of 2026, subject to regulatory approvals.1 Ollin, a privately held Austin company, rounds the milestones to "approximately $1.1 billion".4 Reuters puts the total at up to $3.33 billion.5
The deal had been flagged the evening before. On Sunday 15 November Reuters relayed a Financial Times report, citing people familiar with the matter, that J&J could announce a deal as soon as Monday to buy Ollin for up to $3.4 billion: $2.2 billion upfront and a further $1.2 billion in potential milestones.3 Investing.com's relay added that talks "could still fall apart".6 BioSpace also dates the FT report to Sunday evening.7 The FT article could not be accessed, so these details rest on relays. The FT total was rounded; the announced terms come to about $3.325 billion ($2.2 billion plus about $1.125 billion), so the FT ran about $75M high while the structure matched.13
J&J will "enter into a separate development funding agreement with Blackstone Life Sciences" for Phase 3 of OLN324, contingent on the acquisition closing.1 Blackstone will pay $750 million over multiple years to fully fund Phase 3 and "will be eligible to receive certain regulatory and sales milestone payments as well as single digit royalties"; the amounts and royalty rate were not disclosed.1 This finances J&J's programme and is not a purchase of Ollin from its venture backers, though a different Blackstone arm, Blackstone Multi-Asset Investing, took part in Ollin's Series B.12 The J&J release does not say who pays Blackstone's milestones and royalties; Fierce Biotech says J&J does.8
J&J describes OLN324 as an investigational bispecific antibody targeting VEGF and angiopoietin-2 (Ang2) for wet age-related macular degeneration (AMD) and diabetic macular oedema.1 It hits the same two targets as Roche's Vabysmo.9 Fierce reports Ollin has filed for four Phase 3 trials with primary completion in December 2028; the releases do not say whether dosing has begun.8 The efficacy claims are company-reported: MedCity News says Ollin reported faster and greater structural changes in the eye and numerically better vision gains at 20 weeks against Vabysmo, in a Phase 1b trial presented in July.10 RBC Capital Markets analyst Trung Huynh called the deal a "logical strategic fit" but said it is unclear how "differentiated" OLN324 is in a "very competitive and crowded space", and that the price "appears high".9
OLN324 originated at Shanghai-based Innovent Biologics.9 Ollin launched on 17 September 2025 with an "initial $100 million in financing led by ARCH Venture Partners, Mubadala Capital and Monograph Capital".11 Its $330 million Series B on 24 June 2026 was co-led by new investor TCGX and founding investor ARCH.12 ARCH managing director Paul Berns, Ollin's co-founder and executive chairman, said ARCH "incubated Ollin beginning in 2023 with our colleagues at Monograph Capital and Mubadala".4 No source opened discloses the split of proceeds, any investor's return, or Ollin's valuation.
Why it matters: an ARCH-incubated company founded in 2023 won a $2.2bn upfront sale before any Phase 3 result, with Blackstone due to fund Phase 3 once the deal closes, though investor returns are undisclosed and RBC questions how differentiated OLN324 is.1289
Sources
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology (Johnson & Johnson)
- Blackstone Life Sciences Announces $750 Million R&D Funding Agreement (Blackstone)
- J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says (Reuters (via Investing.com))
- Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired (Ollin Biosciences)
- J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion (Reuters (via CNBC))
- J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports (Investing.com)
- J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial (BioSpace)
- J&J pays $2.2B upfront for Ollin to challenge Roche's Vabysmo (Fierce Biotech)
- J&J bets $2.2B on Ollin's vision loss drug (BioPharma Dive)
- J&J's $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding (MedCity News)
- Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology (Ollin Biosciences)
- Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026 (Ollin Biosciences)